Casma Therapeutics

Series-B
casmatx.com Biotech & Healthcare
Total Funding $46M
Latest Round $46M Series-B
Last Announced Nov 15, 2022
Investors Undisclosed
Decision Makers 6 Available

About Casma Therapeutics

With deep expertise in cellular degradation biology, Casma is advancing targeted therapies for neurodegeneration and beyond.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B
Global Headquarters Undisclosed
Tracked Since Nov 8, 2026

Web & Domain Identity

Official Website casmatx.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile @CasmaTx (421 followers)
LinkedIn Corporate Company Profile

Company Milestones & Timeline

1 Events
  1. Capital Raise

    Raised $46,000,000 · Series-B

    casmatx.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Casma Therapeutics.

Funding History

1 Round
Series-B equity · Nov 15, 2022
$46,000,000 casmatx.com

Founders & Leadership

1

Andrea Ballabio

Founder & Scientific Advisor

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

Recently funded startups
New SaaS launches
Never pay twice for contacts